Brain Neoplasms Clinical Trial
Official title:
Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases
MRI is used in clinical routine for diagnosing brain tumors, but has limitations in identifying tumor grade, true tumor extension and differentiate viable tumor tissue from treatment induced changes and recurrences. Amino acid PET has demonstrated a great potential for defining true tumor volume, differentiate viable tumor tissue from postoperative changes or radiation necrosis, selection of biopsy site, non-invasive grading of gliomas and for treatment planning and therapy response assessment. By combining PET with MRI, the diagnostic accuracy can improve significantly for these patients. More research is however needed to compare the most promising amino acid PET tracers in patients with glioma, but also to assess the diagnostic value of amino acid PET in patients with different brain metastases, where the knowledge concerning the uptake characteristics is limited. Three of the most promising amino acid tracers ([11C]-methyl-methionine (11C-MET), [18F] fluoro-ethyl-tyrosin (18F-FET) and anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (18F-FACBC)) will be evaluated in 3 substudies in this project; WP1 Aminoacid PET/MRI in low and high grade glioma; WP2 Role of 11C-MET in high-grade glioma Gamma Knife® radiosurgery; and WP3 Amino acid PET in brain metastasis. The main aim of the study is to improve diagnostic accuracy, histopathological tissue sampling, delineation of tumor extent and therapy response assessment in gliomas and brain metastases with amino acid PET/MRI.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02810899 -
Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy
|
Phase 4 | |
| Withdrawn |
NCT00977795 -
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00787982 -
Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00555984 -
Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors
|
N/A | |
| Completed |
NCT00038441 -
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03619694 -
Role of MR Spectroscopy in Brain Tumors
|
||
| Withdrawn |
NCT01236586 -
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
|
Phase 1 | |
| Unknown status |
NCT02775136 -
An Evaluation of a Non-invasive Brain Monitor
|
N/A | |
| Completed |
NCT01244737 -
FLT-PET Imaging of Brain Tumors in Children
|
Phase 2 | |
| Completed |
NCT00993057 -
Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia
|
Early Phase 1 | |
| Terminated |
NCT00769093 -
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
|
Phase 1 | |
| Completed |
NCT00392119 -
MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors
|
Phase 1 | |
| Terminated |
NCT00038389 -
Study of Vioxx and Radiation Therapy for Brainstem Glioma
|
Phase 1 | |
| Completed |
NCT00062478 -
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
|
Phase 2 | |
| Recruiting |
NCT05049148 -
Platelets Activation in Brain Neoplasms
|
N/A | |
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Recruiting |
NCT04712721 -
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
|
Early Phase 1 | |
| Completed |
NCT02881957 -
Hypovitaminosis D in Neurocritical Patients
|
Phase 2/Phase 3 | |
| Terminated |
NCT01954576 -
NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
N/A | |
| Recruiting |
NCT05538130 -
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
|
Phase 1 |